Troglitazone for non-insulin-dependent diabetes mellitus.
D000284:Administration, Oral; D002839:Chromans / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003920:Diabetes Mellitus / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D006801:Humans; D006937:Hypercholesterolemia / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009765:Obesity; D013844:Thiazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D045162:Thiazolidinediones; D000077288:Troglitazone
D002839:Chromans; D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D000077288:Troglitazone